Telix Pharmaceuticals signed a strategic agreement on September 21, 2026 to merge with ITM Isotope Technologies Munich SE, in a transaction valued at a minimum of $1.65 billion. The Australian company, dual-listed on the ASX and NASDAQ, is acquiring the entirety of ITM’s shares — a privately held firm headquartered in Munich and recognized as the global leader in therapeutic radioisotope production.
The deal’s total value could rise by an additional $700 million should ITM’s lead drug, ITM-11, meet specific regulatory and commercial milestones — a structure that ties the deal’s upside directly to the performance of the therapeutic pipeline. The merger has already been approved by Telix’s board of directors and, at the time of signing, by holders of more than 90% of ITM’s shares. An extraordinary general meeting of Telix shareholders is expected in November 2026, with closing anticipated before year-end.
ITM is currently the only company in the world producing lutetium-177 (177Lu) at commercial scale globally, and is also active in the production of actinium-225 (225Ac) and terbium-161 (161Tb) — three radioisotopes that form the backbone of next-generation oncological radiopharmaceutical therapies. These drugs work by delivering radioactive isotopes directly to cancer cells with a precision that conventional treatments cannot match. ITM also holds, through an agreement with Isogen, exclusive 15-year access to Bruce Power‘s nuclear reactors in Canada, which are used for the irradiation services required in 177Lu production.
The combined company emerges with an industrial profile that will be difficult to replicate: a globally validated distribution network, a profitable and cash-generative isotope manufacturing business, and the broadest therapeutic pipeline in the sector. Pro forma revenues for the unified group in 2026 are estimated at over $1.3 billion, with a positive EBITDA contribution expected from 2027 onward. For Telix, this represents the most ambitious step in a vertical integration strategy it has been pursuing for years: in April 2026, the company had already entered into a collaboration with Regeneron Pharmaceuticals to develop next-generation radiopharmaceutical therapies, with Regeneron contributing $40 million upfront.
The oncological radiopharmaceutical sector is currently dominated by Novartis, which launched its two flagship treatments in 2018 and 2022, effectively opening the market. The Telix-ITM merger creates the first truly formidable competitor capable of challenging at that scale. Christian Behrenbruch, Managing Director of Telix, described the deal as a response to the consolidation phase the industry is undergoing as it matures. With ITM on board, Telix controls the entire value chain — from isotope production to patient treatment. It is a position few players in the world can claim, and one that will become even more strategically relevant if ITM-11 secures regulatory approval in the coming months.
